ACTONEL PLUS CALCIUM TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

RISEDRONATE SODIUM; CALCIUM (CALCIUM CARBONATE)

から入手可能:

WARNER CHILCOTT CANADA CO

ATCコード:

M05BB02

INN（国際名）:

RISEDRONIC ACID AND CALCIUM, SEQUENTIAL

投薬量:

35MG; 500MG

医薬品形態:

TABLET

構図:

RISEDRONATE SODIUM 35MG; CALCIUM (CALCIUM CARBONATE) 500MG

投与経路:

ORAL

パッケージ内のユニット:

7/28

処方タイプ:

Prescription

治療領域:

BONE RESORPTION INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0251633001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2015-11-19

製品の特徴

_ _
PRODUCT MONOGRAPH
Pr
ACTONEL PLUS CALCIUM
Risedronate Sodium (as the hemi-pentahydrate) 35 mg Tablets
USP
Bone Metabolism Regulator
and
Calcium Carbonate 1250 mg Tablets
USP
Mineral Supplement
Warner Chilcott Canada Co.
PO Box 4367, Station A
Toronto, ON
M5W 3N7
Marketed with sanofi-aventis Canada Inc.
Laval, QC H7L 4A8
Date of Revision:
February 19, 2013
SUBMISSION CONTROL NO: 160238
2
TABLE OF CONTENTS
PAGE
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
............................................................................3
INDICATIONS AND CLINICAL USE
..................................................................................3
CONTRAINDICATIONS
.......................................................................................................4
WARNINGS AND PRECAUTIONS
......................................................................................4
ADVERSE REACTIONS
........................................................................................................7
DRUG INTERACTIONS
......................................................................................................10
DOSAGE AND ADMINISTRATION
..................................................................................13
OVERDOSAGE
.....................................................................................................................14
ACTION AND CLINICAL
PHARMACOLOGY.................................................................15
STORAGE AND STABILITY
..............................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................20
PHARMACEUTICAL INFORMATION
..............................................................................20
CLINICAL TRIALS
.......................................